These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 7909232)

  • 1. Lack of isolate-specific neutralizing activity is correlated with an increased viral burden in rapidly progressing HIV-1-infected patients.
    Lu W; Shih JW; Tourani JM; Eme D; Alter HJ; Andrieu JM
    AIDS; 1993 Nov; 7 Suppl 2():S91-9. PubMed ID: 7909232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing and enhancing antibodies measured in complement-restored serum samples from HIV-1-infected individuals correlate with immunosuppression and disease.
    Füst G; Tóth FD; Kiss J; Ujhelyi E; Nagy I; Bánhegyi D
    AIDS; 1994 May; 8(5):603-9. PubMed ID: 7914732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing antibodies in slowly progressing HIV-1 infection.
    Schønning K; Nielsen C; Iversen J; Nielsen JO; Hansen JE
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(4):400-7. PubMed ID: 7583435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual.
    Montefiori DC; Altfeld M; Lee PK; Bilska M; Zhou J; Johnston MN; Gao F; Walker BD; Rosenberg ES
    J Immunol; 2003 Apr; 170(7):3906-14. PubMed ID: 12646660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes.
    Ruppach H; Nara P; Raudonat I; Elanjikal Z; Rübsamen-Waigmann H; Dietrich U
    J Virol; 2000 Jun; 74(12):5403-11. PubMed ID: 10823844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apoptosis of CD4+ and CD19+ cells during human immunodeficiency virus type 1 infection--correlation with clinical progression, viral load, and loss of humoral immunity.
    Samuelsson A; Broström C; van Dijk N; Sönnerborg A; Chiodi F
    Virology; 1997 Nov; 238(2):180-8. PubMed ID: 9400591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous neutralizing antibody to human immunodeficiency virus-1 and replication-competent virus recovered from CD4+ T-cell reservoirs in pediatric HIV-1-infected patients on HAART.
    Ching N; Nielsen-Saines KA; Deville JG; Wei LS; Garratty E; Bryson YJ
    AIDS Res Hum Retroviruses; 2010 May; 26(5):585-91. PubMed ID: 20455762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.
    Barouch DH; Santra S; Schmitz JE; Kuroda MJ; Fu TM; Wagner W; Bilska M; Craiu A; Zheng XX; Krivulka GR; Beaudry K; Lifton MA; Nickerson CE; Trigona WL; Punt K; Freed DC; Guan L; Dubey S; Casimiro D; Simon A; Davies ME; Chastain M; Strom TB; Gelman RS; Montefiori DC; Lewis MG; Emini EA; Shiver JW; Letvin NL
    Science; 2000 Oct; 290(5491):486-92. PubMed ID: 11039923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating HIV-1-infected cell burden from seroconversion to AIDS: importance of postseroconversion viral load on disease course.
    Lee TH; Sheppard HW; Reis M; Dondero D; Osmond D; Busch MP
    J Acquir Immune Defic Syndr (1988); 1994 Apr; 7(4):381-8. PubMed ID: 7907663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads.
    Pellegrin I; Legrand E; Neau D; Bonot P; Masquelier B; Pellegrin JL; Ragnaud JM; Bernard N; Fleury HJ
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Apr; 11(5):438-47. PubMed ID: 8605588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
    Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
    Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between cell-free viraemia, antigenaemia and antibody levels in HIV-1-infected Ethiopian patients.
    Ayehunie S; Sönnerborg A; Desta B; Kefene H; Zewdie D; Britton S; Strannegård O
    AIDS; 1992 Jul; 6(7):651-7. PubMed ID: 1503684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of virologic, immunologic, and clinical parameters in infants with vertically acquired human immunodeficiency virus type 1 infection.
    Muñoz-Fernández MA; Obregón E; Navarro J; Börner C; Gurbindo MD; Sampelayo TH; Fernández-Cruz E
    Pediatr Res; 1996 Oct; 40(4):597-602. PubMed ID: 8888289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection.
    Montefiori DC; Hill TS; Vo HT; Walker BD; Rosenberg ES
    J Virol; 2001 Nov; 75(21):10200-7. PubMed ID: 11581388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High levels of circulating RNA in patients with symptomatic HIV-1 infection.
    Baumberger C; Kinloch-de-Loës S; Yerly S; Hirschel B; Perrin L
    AIDS; 1993 Nov; 7 Suppl 2():S59-64. PubMed ID: 7909226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing and complement-dependent enhancing antibodies in different stages of HIV infection.
    Tóth FD; Szabó B; Ujhelyi E; Pálóczi K; Horváth A; Füst G; Kiss J; Bánhegyi D; Hollán SR
    AIDS; 1991 Mar; 5(3):263-8. PubMed ID: 1676275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals.
    Connor RI; Mohri H; Cao Y; Ho DD
    J Virol; 1993 Apr; 67(4):1772-7. PubMed ID: 8095306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection.
    Carotenuto P; Looij D; Keldermans L; de Wolf F; Goudsmit J
    AIDS; 1998 Sep; 12(13):1591-600. PubMed ID: 9764777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-level viremia in adults and children infected with human immunodeficiency virus: relation to disease stage and CD4+ lymphocyte levels.
    Saag MS; Crain MJ; Decker WD; Campbell-Hill S; Robinson S; Brown WE; Leuther M; Whitley RJ; Hahn BH; Shaw GM
    J Infect Dis; 1991 Jul; 164(1):72-80. PubMed ID: 1676046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Course of specific T lymphocyte cytotoxicity, plasma and cellular viral loads, and neutralizing antibody titers in 17 recently seroconverted HIV type 1-infected patients.
    Legrand E; Pellegrin I; Neau D; Pellegrin JL; Ragnaud JM; Dupon M; Guillemain B; Fleury HJ
    AIDS Res Hum Retroviruses; 1997 Nov; 13(16):1383-94. PubMed ID: 9359658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.